Bosch John Roderick Ten Sells 1,416 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) SVP Bosch John Roderick Ten sold 1,416 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $120.00, for a total transaction of $169,920.00. Following the transaction, the senior vice president owned 33,552 shares in the company, valued at approximately $4,026,240. This trade represents a 4.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

• On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The stock was sold at an average price of $101.47, for a total transaction of $287,363.04.

Billiontoone Price Performance

Shares of BLLN opened at $120.35 on Friday. The firm has a market cap of $5.53 billion and a PE ratio of 218.82. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The firm has a fifty day simple moving average of $95.54 and a two-hundred day simple moving average of $87.69. Billiontoone, Inc. has a 1-year low of $61.96 and a 1-year high of $138.70.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. The business’s quarterly revenue was up 83.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.39) earnings per share. On average, equities analysts anticipate that Billiontoone, Inc. will post 0.93 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BLLN. Rossby Financial LCC bought a new stake in Billiontoone during the 4th quarter worth approximately $25,000. Wells Fargo & Company MN bought a new position in shares of Billiontoone in the fourth quarter worth approximately $76,000. Smartleaf Asset Management LLC purchased a new stake in shares of Billiontoone in the fourth quarter worth $80,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Billiontoone during the 4th quarter valued at $82,000. Finally, Renaissance Capital LLC bought a new stake in shares of Billiontoone during the 4th quarter valued at $201,000.

Analyst Ratings Changes

BLLN has been the subject of a number of recent research reports. Guggenheim initiated coverage on Billiontoone in a research note on Monday. They set a “buy” rating and a $125.00 price target for the company. Wells Fargo & Company dropped their price objective on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a report on Thursday, March 5th. Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. BTIG Research decreased their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Billiontoone presently has an average rating of “Moderate Buy” and an average target price of $126.00.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.